Comparative Pharmacology
Head-to-head clinical analysis: MOTPOLY XR versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MOTPOLY XR versus NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE.
MOTPOLY XR vs NAPHAZOLINE HYDROCHLORIDE AND PHENIRAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MOTPOLY XR is a combination of an opioid agonist (morphine) and an opioid antagonist (naltrexone). The extended-release formulation allows for sequential release: an initial morphine dose followed by naltrexone, which mitigates opioid-induced adverse effects by antagonizing mu-opioid receptors in the gastrointestinal tract without affecting central analgesia.
Naphazoline is an alpha-adrenergic receptor agonist that causes vasoconstriction of conjunctival blood vessels, reducing redness and edema. Pheniramine is a histamine H1-receptor antagonist that blocks the effects of histamine, reducing itching and allergic symptoms.
Adults: 10 mg orally once daily, with or without food.
1-2 drops or sprays in each nostril every 4-6 hours as needed, not to exceed 5-7 days
None Documented
None Documented
Terminal half-life 12–15 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Naphazoline: Terminal elimination half-life approximately 2-3 hours; clinical effects may persist longer due to local vasoconstriction. Pheniramine: Terminal elimination half-life approximately 14-16 hours; appropriate for twice-daily dosing.
Renal: ~60% unchanged; biliary/fecal: ~25% as metabolites; <5% unchanged in feces.
Naphazoline: Renal excretion of unchanged drug and metabolites accounts for >80% of elimination. Pheniramine: Renal excretion of unchanged drug and metabolites accounts for >90% of elimination, with <5% biliary/fecal elimination.
Category C
Category C
Decongestant/Antihistamine Combination
Ophthalmic Antihistamine/Decongestant